紫杉醇单药维持治疗中晚期非小细胞肺癌的临床研究.pdfVIP

文章编号：1001—5949(2012)11—108803 ·临；床研究· 紫杉醇单药维持治疗中晚期非小细胞肺癌的临床研究 李咏梅，袁葆琳，杨丽娜，陈素琼，吴勇，梁海田周锐 [摘要】 目的观察紫杉醇单药维持治疗中晚期非小细胞肺癌(NSCLC)的疗效及无进展生存期。方法90 例中晚期非小细胞肺癌患者给予一线含铂类的方案4周期化疗后，将达完全缓解(CR)、部分缓解(PR)及稳定 (sD)患者53例分为2组。治疗组27例，给予紫杉醇维持治疗加最佳支持治疗3周期；对照组26例，仅给予最佳 支持治疗，比较2组的有效率、无进展生存期及毒副反应。结果治疗组与对照组无进展生存期分别为(3．63± 组生活质量差异无统计学意义(PO．05)。结论紫杉醇单药维持治疗中晚期非小细胞肺癌可提高疾病控制率、 延长无进展生存期，生活质量不受影响，且毒副反应能耐受。 [关键词]非小细胞肺癌；紫杉醇单药；维持治疗；无进展生存期 [中图分类号]11734．2[文献标识码]A ClinicalofPaclitaxelAloneinMaintenanceTreatmentofAdvancedNon—smmlCell Study Lung Medicalcol- Li一眦，et ofTumor，TheSecond ofNingxia Ⅱ％噌一mei，YUANBao—lin，YANGa1．Department AffiliatedHospital 崛鲈，Yinchuan750001，Ningxia，China of of non— Toassessthe and Paclitaxelaloneinthemaintenancetreatmentadvanced [Abstract]Objective efficacysafety who with cell cancerwereenrolledinthis smallcell cancer．Methods were advancednon—small Ninety diagnosed lung lung patients 4 ofstandard andother or and whodid gemcitabine study．Aftercycles cisplatin drugs(Paelitaxel Navelbine)chemotherapy，53patients not werechosenandthen were dividedintotreatment control in patients progress they randomly group(n=27)andgroup(n=26)．The treatmentreceived aloneandbest the incontrol receivedbest group paclitaxel supportivecare，whilepatients group suppbrt